SEMABIZ, Inc. | ChosaReport.com

日本と海外の市場調査レポート＆サービスを取り扱っております。

医薬品開発・製造受託機関（CDMO）市場 : 2024-2032年

Contract Development and Manufacturing Organization (CDMO) Market Size, Share & Industry Analysis

医薬品開発・製造受託機関（CDMO）市場 : サービス (CMO [API製造、最終製品製造 {固体剤形、注射剤など}、および包装] および CRO [初期段階開発サービス {化学、製造および管理 (CMC)、前臨床サービス、およびディスカバリー}]、臨床 {フェーズ 1、フェーズ 2、フェーズ 3、フェーズ 4}、検査サービス、その他])、および地域別の市場規模、シェア、業界分析および予測、2024-2032年
Contract Development and Manufacturing Organization (CDMO) Market Size, Share & Industry Analysis, By Service (CMO [API Manufacturing, Finished Product Manufacturing {Solid Dosage Forms, Injectables, and Others}, and Packaging] and CRO [Early Phase Development Services {Chemistry, Manufacturing and Controls (CMC), Preclinical Service, and Discovery}, Clinical {Phase 1, Phase 2, Phase 3, and Phase 4}, Laboratory Service, and Others]), and Regional Forecast, 2024-2032

商品番号 : SMB-72341

出版社Fortune Business Insights
出版年月2025年1月
ページ数155
価格タイプシングルユーザライセンス
価格USD 4,850
種別英文調査報告書

Growth Factors of Contract Development and Manufacturing Organization (CDMO) Market

The Contract Development and Manufacturing Organization (CDMO) market size was valued at USD 224.86 billion in 2023, and the market is now projected to grow from USD 242.62 billion in 2024 to USD 465.14 billion by 2032, exhibiting a CAGR of 8.5% during the forecast period of 2024-2032.

医薬品開発・製造受託機関（CDMO）の市場規模は2023年に2,248億6,000万米ドルと評価され、現在市場は2024年の2,426億2,000万米ドルから2032年までに4,651億4,000万米ドルに成長すると予測されており、2024年から 2032年の予測期間中8.5%のCAGRを示しています。

Due to the COVID-19 pandemic, the Contract Development and Manufacturing Organization (CDMO) market growth showed a barely mild advantageous growth in 2020 compared to the preceding 12 months. As a result of this pandemic, the progress of drug development became impeded within the first half of the financial 12 months of 2020. However, many biopharmaceutical and pharmaceutical enterprise gamers ramped up their research and manufacturing efforts in the latter part of 2020 to create and distribute testing kits, vaccines, and medications for the SARS-CoV-2 virus.

医薬品開発・製造受託機関（CDMO）市場 : 2024-2032年
contract_development_and_manufacturing_organization_(cdmo)_market

The Contract Development and Manufacturing Organization (CDMO) market share is growing with the number of continual diseases growing globally due to the populace boom, Western lifestyle adoption, and financial improvement. Pharmaceutical companies are more and more developing powerful scientific products to speed up remedies due to the boom in continual sicknesses and the growing older populace. Moreover, the ability of CDMOs to offer one-forestall-shop offerings inside the production of biopharmaceutical merchandise is one of the elements anticipated to contribute to the global Contract Development and Manufacturing Organization (CDMO) market increase at some point in the forecast period.

Additionally, the competitive panorama of the market for Contract Development and Manufacturing Organization (CDMO) is fragmented. Pharmaceutical organisations are largely specialised in offering speedy improvements to enhance the drug improvement and manufacturing process.

Comprehensive Analysis of Contract Development and Manufacturing Organization (CDMO) Market

The Contract Development and Manufacturing Organization (CDMO) market is segmented into Contract Manufacturing Organization (CMO) and Contract Research Organization (CRO) services. The CMO phase, leading in 2023, includes API manufacturing, completed product production (extensively injectables), and packaging, with API production riding increase due to rising biologics demand. The CRO section contains early-section improvement services, clinical trials, laboratory offerings, and others, with early-section offerings dominating in 2023 due to advancements like in-silico technology and increasing preclinical research. Clinical trials are also growing gradually, supported by growing outsourcing and Research and Development investments in prescribed drugs and biotechnology.

North America held the biggest market share by producing sales of USD 87.03 billion in 2023. Throughout the forecast duration, the vicinity is anticipated to maintain a leading role within the marketplace. The boom of the market is especially attributed to the presence of properly hooked-up CDMOs in this vicinity.

The Contract Development and Manufacturing Organization (CDMO) market is fashioned by using key gamers, inclusive of IQVIA (U.S.), ICON per cent (Ireland), Syneos Health (U.S.), Vetter (Germany), Parexel International (MA) Corporation (U.S.), Recipharm AB (Sweden), and Curia Global, Inc. (U.S.), each contributing thru specialised offerings in scientific trials, manufacturing, and studies across worldwide markets. These groups are riding innovation and performance, addressing the developing demand for outsourced pharmaceutical and biotechnology solutions.

In February 2024 – Novo Holdings introduced the purchase of Catalent, Inc., a settlement improvement production company, at USD 16.5 billion.

Segmentation Table

Global Contract Development and Manufacturing Organization (CDMO) Market Scope

Study Period          2019-2032

Base Year               2023

Forecast Period     2024-2032

Growth Rate          CAGR of 8.5% from 2024-2032

Historical Period  2019-2022

Unit        Value (USD Billion)

Segmentation        By service, and Region

By service

  • CMO

–               Solid Dosage Forms

–               Injectables

–               Others

–               API Manufacturing

–               Finished Product Manufacturing

–               Packaging

  • CRO

–               Chemistry, Manufacturing and Controls (CMC)

–               Preclinical Service

–               Discovery

–               Phase 1

–               Phase 2

–               Phase 3

–               Phase 4

–               Early Phase Development Services

–               Clinical

–               Laboratory Service

–               Others

By Region

  • North America (By Service and Country)

–               U.S.

–               Canada

  • Europe (By Service and Country/Sub-Region)

–               U.K.

–               Germany

–               France

–               Spain

–               Italy

–               Scandinavia

–               Rest of Europe

  • Asia Pacific (By Service and Country/Sub-Region)

–               China

–               Japan

–               India

–               Australia & New Zealand

–               Rest of Asia Pacific

  • Rest of the World (By Service)

Table of Contents

1. Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Market Trends
4. Key Insights
4.1. Number of Clinical Trials Conducted by Key Countries/ Sub-Region, 2022
4.2. Overview: Start-ups and Innovations in the Contract Development and Manufacturing Organization (CDMO) Market
4.3. Overview on Outsourcing of R&D, by Key Pharmaceutical Companies
4.4. R&D Investments, by Key Pharmaceutical and Biotechnological Companies
4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
4.6. Impact of COVID-19 on the Market
5. Global Contract Development and Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2019-2032
5.1. Market Analysis, Insights and Forecast – By Service
5.1.1. CMO
5.1.1.1. API Manufacturing
5.1.1.2. Finished Product Manufacturing
5.1.1.2.1. Solid Dosage Forms
5.1.1.2.2. Injectables
5.1.1.2.3. Others
5.1.1.3. Packaging
5.1.2. CRO
5.1.2.1. Early Phase Development Services
5.1.2.1.1. Chemistry, Manufacturing and Controls (CMC)
5.1.2.1.2. Preclinical Service
5.1.2.1.3. Discovery
5.1.2.2. Clinical
5.1.2.2.1. Phase 1
5.1.2.2.2. Phase 2
5.1.2.2.3. Phase 3
5.1.2.2.4. Phase 4
5.1.2.3. Laboratory Service
5.1.2.4. Others
5.2. Market Analysis, Insights and Forecast – By Region
5.2.1. North America
5.2.2. Europe
5.2.3. Asia Pacific
5.2.4. Rest of the World
6. North America Contract Development and Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2019-2032
6.1. Market Analysis, Insights and Forecast – By Service
6.1.1. CMO
6.1.1.1. API Manufacturing
6.1.1.2. Finished Product Manufacturing
6.1.1.2.1. Solid Dosage Forms
6.1.1.2.2. Injectables
6.1.1.2.3. Others
6.1.1.3. Packaging
6.1.2. CRO
6.1.2.1. Early Phase Development Services
6.1.2.1.1. Chemistry, Manufacturing and Controls (CMC)
6.1.2.1.2. Preclinical Service
6.1.2.1.3. Discovery
6.1.2.2. Clinical
6.1.2.2.1. Phase 1
6.1.2.2.2. Phase 2
6.1.2.2.3. Phase 3
6.1.2.2.4. Phase 4
6.1.2.3. Laboratory Service
6.1.2.4. Others
6.2. Market Analysis, Insights and Forecast – By Country
6.2.1. U.S.
6.2.2. Canada
7. Europe Contract Development and Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2019-2032
7.1. Market Analysis, Insights and Forecast – By Service
7.1.1. CMO
7.1.1.1. API Manufacturing
7.1.1.2. Finished Product Manufacturing
7.1.1.2.1. Solid Dosage Forms
7.1.1.2.2. Injectables
7.1.1.2.3. Others
7.1.1.3. Packaging
7.1.2. CRO
7.1.2.1. Early Phase Development Services
7.1.2.1.1. Chemistry, Manufacturing and Controls (CMC)
7.1.2.1.2. Preclinical Service
7.1.2.1.3. Discovery
7.1.2.2. Clinical
7.1.2.2.1. Phase 1
7.1.2.2.2. Phase 2
7.1.2.2.3. Phase 3
7.1.2.2.4. Phase 4
7.1.2.3. Laboratory Service
7.1.2.4. Others
7.2. Market Analysis, Insights and Forecast – By County/ Sub-region
7.2.1. Germany
7.2.2. U.K.
7.2.3. France
7.2.4. Italy
7.2.5. Spain
7.2.6. Scandinavia
7.2.7. Rest of Europe
8. Asia Pacific Contract Development and Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2019-2032
8.1. Market Analysis, Insights and Forecast – By Service
8.1.1. CMO
8.1.1.1. API Manufacturing
8.1.1.2. Finished Product Manufacturing
8.1.1.2.1. Solid Dosage Forms
8.1.1.2.2. Injectables
8.1.1.2.3. Others
8.1.1.3. Packaging
8.1.2. CRO
8.1.2.1. Early Phase Development Services
8.1.2.1.1. Chemistry, Manufacturing and Controls (CMC)
8.1.2.1.2. Preclinical Service
8.1.2.1.3. Discovery
8.1.2.2. Clinical
8.1.2.2.1. Phase 1
8.1.2.2.2. Phase 2
8.1.2.2.3. Phase 3
8.1.2.2.4. Phase 4
8.1.2.3. Laboratory Service
8.1.2.4. Others
8.2. Market Analysis, Insights and Forecast – By Country/ Sub-region
8.2.1. China
8.2.2. India
8.2.3. Japan
8.2.4. Australia & New Zealand
8.2.5. Rest of Asia Pacific
9. Rest of the World Contract Development and Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2019-2032
9.1. Market Analysis, Insights and Forecast – By Service
9.1.1. CMO
9.1.1.1. API Manufacturing
9.1.1.2. Finished Product Manufacturing
9.1.1.2.1. Solid Dosage Forms
9.1.1.2.2. Injectables
9.1.1.2.3. Others
9.1.1.3. Packaging
9.1.2. CRO
9.1.2.1. Early Phase Development Services
9.1.2.1.1. Chemistry, Manufacturing and Controls (CMC)
9.1.2.1.2. Preclinical Service
9.1.2.1.3. Discovery
9.1.2.2. Clinical
9.1.2.2.1. Phase 1
9.1.2.2.2. Phase 2
9.1.2.2.3. Phase 3
9.1.2.2.4. Phase 4
9.1.2.3. Laboratory Service
9.1.2.4. Others
10. Competitive Analysis
10.1. Global Market Share Analysis (2023)
10.2. Company Profiles
10.2.1. IQVIA
10.2.1.1. Overview
10.2.1.2. Products & services
10.2.1.3. SWOT Analysis
10.2.1.4. Recent Developments
10.2.1.5. Strategies
10.2.1.6. Financials (Based on Availability)
10.2.2. ICON plc
10.2.2.1. Overview
10.2.2.2. Products & services
10.2.2.3. SWOT Analysis
10.2.2.4. Recent Developments
10.2.2.5. Strategies
10.2.2.6. Financials (Based on Availability)
10.2.3. Syneos Health
10.2.3.1. Overview
10.2.3.2. Products & services
10.2.3.3. SWOT Analysis
10.2.3.4. Recent Developments
10.2.3.5. Strategies
10.2.3.6. Financials (Based on Availability)
10.2.4. Vetter
10.2.4.1. Overview
10.2.4.2. Products & services
10.2.4.3. SWOT Analysis
10.2.4.4. Recent Developments
10.2.4.5. Strategies
10.2.4.6. Financials (Based on Availability)
10.2.5. Parexel International (MA) Corporation
10.2.5.1. Overview
10.2.5.2. Products & services
10.2.5.3. SWOT Analysis
10.2.5.4. Recent Developments
10.2.5.5. Strategies
10.2.5.6. Financials (Based on Availability)
10.2.6. Recipharm AB
10.2.6.1. Overview
10.2.6.2. Products & services
10.2.6.3. SWOT Analysis
10.2.6.4. Recent Developments
10.2.6.5. Strategies
10.2.6.6. Financials (Based on Availability)
10.2.7. Curia Global, Inc.
10.2.7.1. Overview
10.2.7.2. Products & services
10.2.7.3. SWOT Analysis
10.2.7.4. Recent Developments
10.2.7.5. Strategies
10.2.7.6. Financials (Based on Availability)
10.2.8. Thermo Fisher Scientific Inc.
10.2.8.1. Overview
10.2.8.2. Products & services
10.2.8.3. SWOT Analysis
10.2.8.4. Recent Developments
10.2.8.5. Strategies
10.2.8.6. Financials (Based on Availability)
10.2.9. Unither
10.2.9.1. Overview
10.2.9.2. Products & services
10.2.9.3. SWOT Analysis
10.2.9.4. Recent Developments
10.2.9.5. Strategies
10.2.9.6. Financials (Based on Availability)
10.2.10. DPT Laboratories, LTD.
10.2.10.1. Overview
10.2.10.2. Products & services
10.2.10.3. SWOT Analysis
10.2.10.4. Recent Developments
10.2.10.5. Strategies
10.2.10.6. Financials (Based on Availability)
10.2.11. NextPharma Technologies
10.2.11.1. Overview
10.2.11.2. Products & services
10.2.11.3. SWOT Analysis
10.2.11.4. Recent Developments
10.2.11.5. Strategies
10.2.11.6. Financials (Based on Availability)
10.2.12. Lonza
10.2.12.1. Overview
10.2.12.2. Products & services
10.2.12.3. SWOT Analysis
10.2.12.4. Recent Developments
10.2.12.5. Strategies
10.2.12.6. Financials (Based on Availability)

医療・医薬の最新記事8件